Psoriasis is a chronic inflammatory skin disease with a strong genetic predisposition and autoimmune pathogenic traits [1].

It is a skin disorder that causes skin cells to multiply up to 10 times faster than normal, making the skin build up into bumpy red patches covered with white scales [2].


There are several types of psoriasis [3]. These include:

  • Plaque psoriasis.
  • Nail psoriasis.
  • Guttate psoriasis.
  • Inverse psoriasis.
  • Pustular psoriasis.
  • Erythrodermic psoriasis.
  • Psoriatic arthritis.

Psoriasis develops due to a number of factors such as:

  • a deficiency of IL-10 and TGF-β in serum and skin [4,5,6].
  • the hyperactivity of Th17 and the dysfunction of Treg [7,8].
  • significantly low plasma levels of sHLA-G and IL-10 [9,10].
  • Th17 and IL-17 causing psoriatic plaques and inflammation [11,12].
  • a decrease in FOXP3 and an increase in IL-17-producing Tregs [13].
  • an excessively aberrant Th1/Th2 homeostasis and Th17/Treg balance [14,15,16,17].
  • dendritic cells producing IL-12, IL-23, IL-6 that enable psoriatic inflammation [17].
  • psoriatic lesions over-expressing Bcl-XL making psoriatic keratinocytes particularly resistant to cellular death (apoptosis) [18]


How Our Products Can Treat Psoriasis

We use products derived from the umbilical cord tissues of human babies in all our therapy programs - Wharton's Jelly MSCs (wjMSCs). wjMSCs have been proven to be able to:

  • produce IL-10 and TGF-β [19,20,21,22].
  • inhibit the maturation and activation of dendritic cell precursors [20].
  • express HLA-G [20,21,24,25].
  • inhibit the proliferative response of Th1 and Th17 and augment Th2 and Treg [22].
  • produce IL-35, which induces the proliferation of Treg cell populations thereby reducing the activity of Th17 and Th1 cells [23].
  • up-regulate the induction of apoptosis by attenuating Bcl-2, Bcl-XL activation [24,28].
  • inhibit the activity of the Thl7 cell and reduce the expression of interleukin IL-17 [26].
  • modulate FoxP3 and RORγt expression, leading to the conversion of Th17 into Treg cells [27].
  • migrate to sites of injury (chemotaxis) [29,30,31].
  • communicate with and alter nearby cells (paracrine effect) [32,33,34].
  • encourage your cells to self-repair (autocrine effect) [32,35,36].
  • prevent rejection by regulating the immune system (immunomodulation) [30,31,37,38,39,40,41,42].
  • incapable of forming tumours [30,40,43,44,45].


Treating Psoriasis

There are currently numerous human clinical trials exploring the use of various types of MSCs in the treatment of psoriasis. These have been registered but results and findings have yet to be posted [46,47,48,49,50,51,52].

In 1985, researchers at the University of Alberta, Canada, treated a 29-year-old man suffering from severe polyarthritis with donor (allogeneic) hematopoietic MSCs (hMSCs) taken from his histo-compatible sister. The patient’s psoriasis improved rapidly to normal skin within 6 months. There was no active synovitis. He resumed work and an active lifestyle. His psoriasis remained in remission for 12 months. 5 years post-treatment, the patient only has had mild psoriasis of the scalp and occasional brief flares of synovitis in the left ankle. In 1998, 13 years after hMSCs transplantation, the patient developed more widespread arthritis of the wrists, small joints of his hands, feet and left knee and was treated with a course of hydroxychloroquine. At the time of reporting in 2005, 20 years after allogeneic hMSCs, the patient has not had any major disability and only uses anti-inflammatory agents to manage his arthritis [53].

In 2012, doctors from the Children’s Mercy Hospitals and Clinics as well as researchers from the University of Missouri, School of Medicine treated a 9-year-old boy with high-dose chemotherapy (HDCT) followed by a transfusion of the patient’s own (autologous) bone marrow MSCs (bmMSCs). The patient presented with a history of guttate psoriasis and a 1-month history of back pain; which progressively worsened and involved pain in the lower extremities. Further evaluation confirmed a diagnosis of L3 Ewing’s sarcoma. When the patient was discharged 20 days after treatment, he had nearly a complete resolution of his skin lesions. At the time of reporting, 15 months post-transplantation, the patient continued to show resolution of his guttate lesions [54].

In August of that year, specialists from the Tokyo Metropolitan Cancer and Infectious Diseases Centre, Japan treated a 54‐year‐old man suffering from myelodysplastic syndrome (MDS) and a 10‐year history of intractable psoriasis vulgaris. After a myeloablative conditioning regimen (comprising of busulfan and cyclophosphamide), the patient was treated with allogeneic bone marrow (bmMSCs) from a histo-compatible donor. The patient’s skin lesions improved immediately and dramatically post-transplantation with remission of both his MDS and psoriasis maintained at the time of reporting; 8 months post-transplantation [55].

In 2016, researchers from the University of Texas treated a 35-year-old Caucasian male who had a 15-year history of psoriasis vulgaris and psoriatic arthropathy. Further testing confirmed a diagnosis of multiple myeloma. 50% of the patient’s body was covered in numerous symmetrically-distributed erythematous plaques with silvery scales of psoriasis vulgaris mainly affecting his scalp, forehead, ears, back, upper chest and abdomen. Additional scaled guttate plaques affected the patient’s elbows and knees while his nails exhibited distal onycholysis. After a myeloablative conditioning regimen (comprising of melphalan), he was treated with autologous bone marrow MSCs (bmMSCs). The patient experienced a complete 1-year remission of myeloma, accompanied by complete regression of his psoriatic arthropathies and skin lesions (without the use of corticosteroids or phototherapy). The patient also noted a complete resolution of the arthralgias, from which he had suffered for more than a decade, despite remaining untreated for them. At the time of reporting 15 months post-transplantation, he remains psoriasis- and arthralgia-free although his myeloma has relapsed [56].

Two years later, doctors from Florida-based MSC clinic treated a patient with severe psoriasis using 60ml of autologous adipose-derived MSCs (adMSCs) injected via an intravenous push. The patient demonstrated a significant decrease in symptoms, with a noticeable difference in skin quality appearance. Psoriasis area and severity index score went from 50.4 (at baseline) to 0.3 at the 1-month follow-up [57].

In 2019, Indian and American researchers treated a 38-year-old male who had been suffering from psoriasis vulgaris for 2 years with MSC–conditioned media (MSC-CM). A preliminary examination showed numerous erythematous plaques, with silvery scales, present all over the patient's scalp as well as the region behind the ears. The severity of the disease was assessed to be 28 on the Psoriasis Scalp Severity Index (PSSI). 100ml of allogeneic adipose tissue was aspirated from the waist area of a healthy donor via lipoaspiration. The adipose tissue was then subjected to enzymatic digestion and centrifugation before being cultured in DMEM medium. The MSC-CM was topically applied on the patient’s afflicted areas once a day over a period of 1 month. 2 weeks into the treatment, the erythematous plaques and silvery scales were found to have significantly declined and were completely cleared by the end of treatment. The PSSI score reduced to 0 (from 28) and regression was observed at the 6-month follow-up. The patient did not take any other medication during the 6-month assessment period and had an improved quality of life without any adverse side effects [58].


Cyrona’s Program

Achieving high standards in our work is of paramount importance to us. Depending on a patient’s needs, we combine our premium grade Passage 2 wjMSCs with physiotherapy, occupational therapy, speech and language therapy and/or rehabilitative medicine. 

Learn more about our Products and Programs.


Why Choose Cyrona?

  • Latest cellular research and technology.
  • Unique, tailored therapy outlines.
  • Products that meet international standards.
  • Microbiology & clinical team with extensive experience in advanced medicine.
  • Board-certified physicians geared toward patient safety.
  • Fact-based information from clinical studies and trials.
  • No outlandish promises of a one-stop-cure or false improvement rates.


Therapy Packages

All our therapy packages come inclusive of:



  • Premium grade Passage 2 wjMSCs.
  • Treatment by qualified specialist(s).
  • Certificate of Analysis (CoA).
  • Airport transfer.
  • Transportation to & from therapy session(s).
  • Accommodation.
  • Hospital room for therapy.



  • Premium grade Passage 2 wjMSCs.
  • Treatment by qualified specialist(s).
  • Certificate of Analysis (CoA).
  • Transportation to & from therapy session(s).
  • Hospital room for therapy.


How Do We Proceed

All our therapies are charged based on the number of wjMSCs and supplementary infusions required for the patient’s specific condition. As no two people are alike, our specialists review each patient’s medical reports before tailoring a therapy catered to addressing his or her individual needs.

You may chat with one of our Customer Care Representatives or send an e-mail detailing the patient’s condition to one of our Liaison Officers. It would expedite the process if you can provide us with:

  • Imaging results (MRI scan / CT scan / X-Ray).
  • Haematology reports (blood test).
  • Doctor’s assessment reports.
  • Pictures or videos of the patient (if relevant).

Upon getting in touch with us, a Liaison Officer evaluates and assigns the case to the specialist best equipped to treat the condition. A therapy, unique only to the patient, is drawn up and a price quoted accordingly.

Should you decide to proceed with therapy, our specialists require that all patients have Cancer Marker Screening performed in their country of residence before travelling to us for therapy. If the patient has had Cancer Marker Screening within the last 3 months, you may e-mail those results to us. In the event that the patient’s Cancer Marker Screening results are not satisfactory, our specialists will refuse to proceed with therapy. It is for this reason that we request that patients have Cancer Marker Screening performed in their country of residence prior to travelling to us.

One week prior to arrival, a deposit payment is required in order to arrange accommodation and transportation.

Full payment is required to be made one-day prior to therapy commencement.

Post-treatment, our specialist will provide the patient with a post-treatment protocol as well as what to expect on his or her journey towards a better, and hopefully, healthier new life.


Kindly get in touch with us for the sources listed throughout this article.


More than 1000 people are choosing Cyrona Health


Our Facilities

Download our complimentary eBook!

Fill in the form to download our complimentary eBook and subscribe to our newsletter to receive exclusive information regarding our therapies and limited time promotions. Get in touch with us here. Or chat with a Customer Service Representative now.

General Cyrona Cell eBook